New User:

Forgot your password?

Stock Market & Financial Investment News

News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 >>
October 2, 2015
08:21 EDTCVSAmazon to be number two player in U.S. consumables by 2018, says Cowen
John Blackledge and the research team at Cowen project that (AMZN) will grow to be the number two player in the $425B market for U.S. consumables - which they define as personal care, household, pet and baby products - by 2018. The firm expects Amazon to use its multi-platform approach, centered around Prime, to help the e-commerce giant gain share in consumables at the expense of Wal-Mart (WMT), Target (TGT), Walgreens (WBA) and CVS Health (CVS). Cowen has Outperform ratings on Amazon and Target and a Market Perform rating on shares of Wal-Mart.
October 1, 2015
13:58 EDTSNYExpress Scripts hints at slow start for new cholesterol drugs
An interview with Express Scripts' (ESRX) Everett Neville hinted at slow adoption rates for a pair of new cholesterol treatments known as PCSK9 inhibitors, spurring Piper Jaffray analysts to weigh in on the matter this morning. REJECTION RATES: In a Reuters interview published Wednesday, Express Scripts VP of Pharma Strategies and Chief Trade Relations Officer Everett Neville commented that two new PCSK9 drugs would not be "budget busters" because most prescriptions for the treatments are actually being denied. Praluent from Regeneron (REGN) and Sanofi (SNY) as well as Amgen's (AMGN) Repatha were approved in recent months to treat high cholesterol, but their $14,000-plus yearly costs have come under fire, including from the Institute for Clinical and Economic Review. "We're seeing a lot of patients who either don't qualify or their physicians are not providing [necessary] information," Neville explained, indicating that use of the cholesterol treatments is coming in at the low end of expectations. ANALYST BREAKDOWN: Piper Jaffray analyst Edward Tenthoff said Neville's statements "validate" his view that PCSK9 adoption rates would be vulnerable to pushback from reimbursers like Express Scripts. Tenthoff added that he continues to see a slow launch for Regeneron's Praluent in particular, especially given the lack of cardiovascular outcomes data. Fellow Piper Jaffray analyst Joshua Schimmer took a more optimistic view, acknowledging the apparently high prescription rejection rate but arguing that the patient pool for the drugs is expected to "grow substantially" once cardiovascular data is released. PRICE ACTION: Express Scripts shares have slipped roughly 0.9% amid broader market losses, while shares of Regeneron, Sanofi, and Amgen are all showing minor declines of less than 1%.
13:00 EDTSNYAlnylam recent weakness a buying opportunity, says Piper Jaffray
Subscribe for More Information
10:50 EDTCVSLeerink healthcare services analyst holds analyst/industry conference call
Analyst Larsen, along with Dan Steiber of D2 Pharma Consulting and James Kenney, Jr., of Harvard Pilgrim Health Care, discuss Hillary Care's potential impact to the Prescription Drug Supply Chain, the impact of the Medicaid rebate program and the uptake of bio-similars and generic launches in 2015 on an Analyst/Industry conference call to be held on October 2 at 12 pm.
08:56 EDTSNYSanofi launches authorized generic version of Arava for arhritis
Subscribe for More Information
07:32 EDTWBMDWebMD reaffirms FY15 revenue $625M-$635M, consensus $629.50M
Sees FY15 adjusted EBITDA to be at or slightly above previous guidance of $185M-$195M.
07:01 EDTSNYGenzyme opts into ALN-AT3 Hemophilia Program
Subscribe for More Information
September 30, 2015
17:34 EDTSNYExpress Scripts says many PCSK9 prescriptions denied, Reuters reports
Subscribe for More Information
10:47 EDTCVSLeerink analyst/industry conference call date/time changed from October 8 10 am
Healthcare Distribution & Technology Larsen, along with Diplomat Pharmacy Chairman & CEO Hagerman and CFO & Secretary/Treasurer Whelan, provide industry insights including the potential impact of Hillary Care, the influence CMS may have on overall drug pricing and recent stock volatility on an Analyst/Industry conference call now being held at a new date and time of September 30 at 5 pm.
09:05 EDTCVSCVS Health announces partnership with MassChallenge and Rock Health
CVS Health announced that it was partnering with top startup accelerator MassChallenge and digital health venture fund Rock Health to drive faster innovation and expand areas of focus for connected health solutions.
September 29, 2015
17:11 EDTWBMDWebMD announces commitment on additional shares for long-term incentive plan
WebMD is making a commitment that none of the 1.7M additional shares to be made available for grant under its 2005 Long-Term Incentive Plan will be used for grants to members of WebMD's Board of Directors or to WebMD's executive officers, except in the case of a new hire who joins WebMD as an executive officer.
12:35 EDTSNYPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
10:22 EDTWBMDABC clarifies that WebMD doesn't sell identifiable personal information of users
Subscribe for More Information
08:07 EDTSNYSanofi announces FDA accepted filing of NDA for lixisenatide
Subscribe for More Information
05:16 EDTSNYSanofi announces NDA for Lixisenatide accepted for review by FDA
Subscribe for More Information
<< 1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use